APO-LINEZOLID 600 MG
LINEZOLID : 600 MG · DIN 02426552 · APOTEX INC
Health Canada status: MARKETED
What is APO-LINEZOLID?
APO-LINEZOLID 600 MG contains LINEZOLID : 600 MG. It is listed in the Health Canada Drug Product Database under DIN 02426552, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 31-Oct-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-LINEZOLID used for?
Treatment of adult patients with susceptible Gram-positive infections: VREF, nosocomial/community-acquired pneumonia, and complicated/uncomplicated skin and skin structure infections.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02426552 |
|---|---|
| Brand name | APO-LINEZOLID |
| Generic / active ingredient | LINEZOLID : 600 MG |
| Manufacturer | APOTEX INC |
| Strength | 600 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01XX08 LINEZOLID |
| AHFS class | 08:12.28.24 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Oct-2019 |
| Original market date | 2014-08-19 00:00:00 |
How is it administered?
Adults: 400 mg or 600 mg orally every 12 hours. Duration: 10 to 28 days depending on infection. May be taken with or without food. No dose adjustment for IV to oral switch.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Section 11 header present but content missing), though typically 15-30°C for such forms.
How is it supplied?
Bottles of 20 and 30 tablets.
Contraindications
Hypersensitivity to linezolid; use of MAOIs within 2 weeks; unless monitored: uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome; specific sympathomimetic/serotonergic drugs.
Warnings and precautions
Myelosuppression (monitor CBC weekly); lactic acidosis; serotonin syndrome; peripheral/optic neuropathy (usually >28 days); Clostridioides difficile-associated disease; hypoglycemia in diabetics.
Is LINEZOLID in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01XX08 LINEZOLID. 8 of 19 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP LINEZOLID | 600 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02520354 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02539748 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02430827 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02481278 |
| SANDOZ LINEZOLID | 600 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02422689 |
| ZYVOXAM | 100 MG / 5 ML | POWDER FOR SUSPENSION | PFIZER CANADA ULC | MARKETED | DIN 02243686 |
| ZYVOXAM | 2 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02243685 |
| LINEZOLID | 600 MG | TABLET | PANDA PHARMACEUTICALS INC. | CANCELLED PRE MARKET | DIN 02457903 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02429527 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02402637 |
Who else supplies LINEZOLID worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LINEZOLID appears in 784 registered pack listings across 12 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.